In the BioHarmony Drug Report Database

"Preview" Icon

Alogliptin

Nesina, Vipidia (alogliptin) is a small molecule pharmaceutical. Alogliptin was first approved as Nesina on 2013-01-25. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Oseni’s patents are valid until 2029-06-16 (FDA).

 

Trade Name

 

Vipidia
 

Common Name

 

alogliptin
 

ChEMBL ID

 

CHEMBL376359
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Dipeptidyl aminopeptidase-IV inhibitors

Image (chem structure or protein)

Alogliptin structure rendering